# Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

> **NCT02278588** · — · COMPLETED · sponsor: **State University of New York at Buffalo** · enrollment: 45 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Rasagiline

## Key facts

- **NCT ID:** NCT02278588
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02278588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02278588, "Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02278588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*